Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AB1 | P08238 | 13/20 | 0.70 |
| ▸ | HSP90AA1 | P07900 | 13/20 | 0.70 |
| ▸ | TRAP1 | Q12931 | 5/20 | 0.61 |
| ▸ | HSP90B1 | P14625 | 3/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10214759 | 0.98 | HSP90AB1 (0.73) | HSP90AB1HSP90AA1TRAP1HSP90B1 | |
| Hydrochloric Acid SCHEMBL382762 | 0.97 | HSP90AB1 (0.72) | HSP90AB1HSP90AA1TRAP1HSP90B1 | |
| SCHEMBL12802789 | 0.87 | TRAP1 (0.57) | HSP90AB1HSP90AA1TRAP1HSP90B1 | |
| SCHEMBL384828 | 0.86 | HSP90AA1 (0.67) | HSP90AB1HSP90AA1HSP90B1 | |
| SCHEMBL19339155 | 0.83 | HSP90AB1 (0.69) | HSP90AB1HSP90AA1HSP90B1 | |
| SCHEMBL30091904 | 0.83 | HSP90AB1 (1.00) | HSP90AB1HSP90AA1TRAP1HSP90B1 | |
| SCHEMBL383624 | 0.83 | HSP90AB1 (1.00) | HSP90AB1HSP90AA1TRAP1HSP90B1 | |
| SCHEMBL30091906 | 0.83 | HSP90AB1 (1.00) | HSP90AB1HSP90AA1TRAP1HSP90B1 | |
| SCHEMBL382859 | 0.80 | HSP90AA1 (0.66) | HSP90AB1HSP90AA1HSP90B1 | |
| SCHEMBL383757 | 0.78 | HSP90AA1 (0.74) | HSP90AB1HSP90AA1TRAP1HSP90B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8530469-B2 | Therapeutic combinations of hydroxybenzamide derivatives as inhibitors of HSP90 | ASTEX THERAPEUTICS LTD. (GB) | 2013-09-10 | — | — | US | disclosed |
| US-20120251545-A1 | Therapeutic Combinations Of Hydroxybenzamide Derivatives As Inhibitors Of HSP90 | ASTEX THERAPEUTICS LIMITED (GB) | 2012-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120251545-A1 | Therapeutic Combinations Of Hydroxybenzamide Derivatives As Inhibitors Of HSP90 | HSP90AB1, HSP90AB2P, HSP90AA1 | HSP90AB1 1/4885HSP90AA1 3/4885TRAP1 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.